{"id":870182,"date":"2025-08-04T14:09:00","date_gmt":"2025-08-04T18:09:00","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/metavia-announces-ai-driven-collaboration-with-syntekabio-to-explore-additional-indications-for-da-1241\/"},"modified":"2025-08-04T14:09:00","modified_gmt":"2025-08-04T18:09:00","slug":"metavia-announces-ai-driven-collaboration-with-syntekabio-to-explore-additional-indications-for-da-1241","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/metavia-announces-ai-driven-collaboration-with-syntekabio-to-explore-additional-indications-for-da-1241\/","title":{"rendered":"MetaVia Announces AI-Driven Collaboration with Syntekabio to Explore Additional Indications for DA-1241"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n Partnership Leverages Syntekabio’s DeepMatcher\u00ae Platform to Expand the Therapeutic Potential of
MetaVia’s Oral GPR119 Agonist<\/i>\n <\/p>\n

\n
\n CAMBRIDGE, Mass.<\/span>
\n <\/span>, Aug. 4, 2025<\/span><\/span> \/PRNewswire\/ — MetaVia Inc. <\/b>(Nasdaq: MTVA),\u00a0a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced a research collaboration with Syntekabio, Inc., a leading artificial intelligence (AI)-driven drug discovery company, to identify additional disease targets and optimize the therapeutic profile of DA-1241, MetaVia’s novel oral G-Protein-Coupled Receptor 119 (GPR119) agonist.<\/p>\n

\n

\n
\n \"MetaVia
\n <\/a>\n <\/p>\n<\/p><\/div>\n

This collaboration follows positive results from MetaVia’s 16-week, 109-subject Phase 2a study of DA-1241, which demonstrated a favorable safety and tolerability profile alongside both hepatoprotective and glucose-regulating effects in presumed metabolic dysfunction-associated steatohepatitis (MASH) patients.<\/p>\n

“The strong safety and tolerability profile shown in our Phase 2a data gives us confidence in DA-1241’s broader therapeutic potential,” stated Hyung Heon Kim<\/span>, President and Chief Executive Officer of MetaVia. “Building on this clinical foundation, we are collaborating with Syntekabio to strategically expand the potential value of DA-1241. Specifically, we will leverage \u00a0their proprietary DeepMatcher\u00ae compound-protein interaction (CPI) AI prediction platform to conduct large-scale virtual screening against more than 1,700 validated protein targets to uncover new, high-potential indications while ensuring specificity and minimizing the risk of off-target effects. This data-driven approach will allow us to accelerate discovery and maximize the value of DA-1241. We believe this unique oral, well-tolerated candidate has the potential to address a range of unmet needs, and we look forward to initial insights from the collaboration later this year.”<\/p>\n

\n About DA-1241
<\/b>DA-1241 is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist with development optionality as a standalone and\/or combination therapy for both MASH and type 2 diabetes (T2D). Agonism of GPR119 in the gut promotes the release of key gut peptides GLP-1<\/span>, GIP, and PYY. These peptides play a further role in glucose metabolism, lipid metabolism and weight loss. DA-1241 has beneficial effects on glucose, lipid profile and liver inflammation, supported by potential efficacy demonstrated during in vivo preclinical studies. The therapeutic potential of DA-1241 has been demonstrated in multiple pre-clinical animal models of MASH and T2D where DA-1241 reduced hepatic steatosis, inflammation, fibrosis, and improved glucose control.\u00a0Furthermore, in Phase\u00a01a, 1b<\/span> and 2a trials, DA-1241 was well tolerated in both healthy volunteers and those with T2DM. In a Phase 2a clinical study, DA-1241 demonstrated direct hepatic action in addition to its glucose lowering effects.<\/p>\n

\n About Syntekabio
<\/b>Syntekabio Co., Ltd. (KOSDAQ: 226330) is a drug discovery company bringing together biology and AI\/ML since 2009 and facilitating the discovery of first-in-class and best-in-class compounds, rapidly. The company has its own supercomputer cloud, along with a global contract research organization network to complement and validate its computational results. Syntekabio offers clients a one-stop shop, with technologies and tailored services to rapidly generate and optimize drug candidates from target to IND-enabling. Syntekabio’s disease-agnostic platform generates a continual stream of hits, leads, and drug candidates that are readily available for purchase. The company also undertakes client-specific projects to identify highly promising development candidates for specific targets and indications.<\/p>\n

\n About MetaVia
<\/b>MetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. The company is currently developing DA-1726 for the treatment of obesity and is developing DA-1241 for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH). DA-1726 is a novel oxyntomodulin (OXM) analogue that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist. OXM is a naturally-occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure, thus potentially resulting in superior body weight loss compared to selective GLP1R agonists. In a Phase 1 multiple ascending dose (MAD) trial in obesity, DA-1726 demonstrated best-in-class potential for weight loss, glucose control, and waist reduction. DA-1241 is a novel G-protein-coupled receptor 119 (GPR119) agonist that promotes the release of key gut peptides GLP-1<\/span>, GIP, and PYY. In pre-clinical studies, DA-1241 demonstrated a positive effect on liver inflammation, lipid metabolism, weight loss, and glucose metabolism, reducing hepatic steatosis, hepatic inflammation, and liver fibrosis, while also improving glucose control. In a Phase 2a clinical study, DA-1241 demonstrated direct hepatic action in addition to its glucose lowering effects.<\/p>\n

For more information, please visit www.metaviatx.com<\/a>.<\/p>\n

\n Forward Looking Statements
<\/b>Certain statements in this press release may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “believes”, “expects”, “anticipates”, “may”, “will”, “should”, “seeks”, “approximately”, “potential”, “intends”, “projects”, “plans”, “estimates” or the negative of these words or other comparable terminology (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including, without limitation, those risks associated with MetaVia’s ability to execute on its commercial strategy; our expectations regarding the sufficiency of our existing cash on hand to fund our operations; the timeline for regulatory submissions; the ability to obtain regulatory approval through the development steps of MetaVia’s current and future product candidates; the ability to realize the benefits of the license agreement with Dong-A ST Co. Ltd., including the impact on future financial and operating results of MetaVia; the cooperation of MetaVia’s contract manufacturers, clinical study partners and others involved in the development of MetaVia’s current and future product candidates; potential negative interactions between MetaVia’s product candidates and any other products with which they are combined for treatment; MetaVia’s ability to initiate and complete clinical trials on a timely basis; MetaVia’s ability to recruit subjects for its clinical trials; whether MetaVia receives results from MetaVia’s clinical trials that are consistent with the results of pre-clinical and previous clinical trials; impact of costs related to the license agreement, known and unknown, including costs of any litigation or regulatory actions relating to the license agreement; the effects of changes in applicable laws or regulations; the effects of changes to MetaVia’s stock price on the terms of the license agreement and any future fundraising; and other risks and uncertainties described in MetaVia’s filings with the Securities and Exchange Commission, including MetaVia’s most recent Annual Report on Form 10-K. Forward-looking statements speak only as of the date when made. MetaVia does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.<\/p>\n

Certain statements in this press release may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “believes”, “expects”, “anticipates”, “may”, “will”, “should”, “seeks”, “approximately”, “potential”, “intends”, “projects”, “plans”, “estimates” or the negative of these words or other comparable terminology (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including, without limitation, those risks associated with MetaVia’s ability to execute on its commercial strategy; our expectations regarding the sufficiency of our existing cash on hand to fund our operations; the timeline for regulatory submissions; the ability to obtain regulatory approval through the development steps of MetaVia’s current and future product candidates; the ability to realize the benefits of the license agreement with Dong-A ST Co. Ltd., including the impact on future financial and operating results of MetaVia; the cooperation of MetaVia’s contract manufacturers, clinical study partners and others involved in the development of MetaVia’s current and future product candidates; potential negative interactions between MetaVia’s product candidates and any other products with which they are combined for treatment; MetaVia’s ability to initiate and complete clinical trials on a timely basis; MetaVia’s ability to recruit subjects for its clinical trials; whether MetaVia receives results from MetaVia’s clinical trials that are consistent with the results of pre-clinical and previous clinical trials; impact of costs related to the license agreement, known and unknown, including costs of any litigation or regulatory actions relating to the license agreement; the effects of changes in applicable laws or regulations; the effects of changes to MetaVia’s stock price on the terms of the license agreement and any future fundraising; and other risks and uncertainties described in MetaVia’s filings with the Securities and Exchange Commission, including MetaVia’s most recent Annual Report on Form 10-K. Forward-looking statements speak only as of the date when made. MetaVia does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.<\/p>\n

\n Contacts:<\/b>\n <\/p>\n

\n MetaVia
<\/b>
\n Marshall H. Woodworth<\/span>
\n
Chief Financial Officer
+1-857-299-1033
marshall.woodworth@metaviatx.com<\/a><\/p>\n

\n
\n Rx Communications Group<\/a>
\n
\n <\/b>
\n Michael Miller<\/span>
\n
+1-917-633-6086
mmiller@rxir.com<\/a><\/p>\n

\n \"Cision\" View original content to download multimedia:https:\/\/www.prnewswire.com\/news-releases\/metavia-announces-ai-driven-collaboration-with-syntekabio-to-explore-additional-indications-for-da-1241-302520330.html<\/a><\/p>\n

SOURCE MetaVia Inc.<\/p>\n<\/p><\/div>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

PR Newswire Partnership Leverages Syntekabio’s DeepMatcher\u00ae Platform to Expand the Therapeutic Potential of MetaVia’s Oral GPR119 Agonist CAMBRIDGE, Mass. , Aug. 4, 2025 \/PRNewswire\/ — MetaVia Inc. (Nasdaq: MTVA),\u00a0a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced a research collaboration with Syntekabio, Inc., a leading artificial intelligence (AI)-driven drug discovery company, to identify additional disease targets and optimize the therapeutic profile of DA-1241, MetaVia’s novel oral G-Protein-Coupled Receptor 119 (GPR119) agonist. This collaboration follows positive results from MetaVia’s 16-week, 109-subject Phase 2a study of DA-1241, which demonstrated a favorable safety and tolerability profile alongside both hepatoprotective and glucose-regulating effects in presumed metabolic dysfunction-associated steatohepatitis (MASH) patients. “The strong safety and tolerability profile shown in our Phase 2a data … <\/p>\n

Continue reading “MetaVia Announces AI-Driven Collaboration with Syntekabio to Explore Additional Indications for DA-1241”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-870182","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nMetaVia Announces AI-Driven Collaboration with Syntekabio to Explore Additional Indications for DA-1241 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/metavia-announces-ai-driven-collaboration-with-syntekabio-to-explore-additional-indications-for-da-1241\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"MetaVia Announces AI-Driven Collaboration with Syntekabio to Explore Additional Indications for DA-1241 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire Partnership Leverages Syntekabio’s DeepMatcher\u00ae Platform to Expand the Therapeutic Potential of MetaVia’s Oral GPR119 Agonist CAMBRIDGE, Mass. , Aug. 4, 2025 \/PRNewswire\/ — MetaVia Inc. (Nasdaq: MTVA),\u00a0a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced a research collaboration with Syntekabio, Inc., a leading artificial intelligence (AI)-driven drug discovery company, to identify additional disease targets and optimize the therapeutic profile of DA-1241, MetaVia’s novel oral G-Protein-Coupled Receptor 119 (GPR119) agonist. This collaboration follows positive results from MetaVia’s 16-week, 109-subject Phase 2a study of DA-1241, which demonstrated a favorable safety and tolerability profile alongside both hepatoprotective and glucose-regulating effects in presumed metabolic dysfunction-associated steatohepatitis (MASH) patients. “The strong safety and tolerability profile shown in our Phase 2a data … Continue reading "MetaVia Announces AI-Driven Collaboration with Syntekabio to Explore Additional Indications for DA-1241"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/metavia-announces-ai-driven-collaboration-with-syntekabio-to-explore-additional-indications-for-da-1241\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-04T18:09:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/2568660\/MetaVia_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"8 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/metavia-announces-ai-driven-collaboration-with-syntekabio-to-explore-additional-indications-for-da-1241\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/metavia-announces-ai-driven-collaboration-with-syntekabio-to-explore-additional-indications-for-da-1241\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"MetaVia Announces AI-Driven Collaboration with Syntekabio to Explore Additional Indications for DA-1241\",\"datePublished\":\"2025-08-04T18:09:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/metavia-announces-ai-driven-collaboration-with-syntekabio-to-explore-additional-indications-for-da-1241\\\/\"},\"wordCount\":1524,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/metavia-announces-ai-driven-collaboration-with-syntekabio-to-explore-additional-indications-for-da-1241\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2568660\\\/MetaVia_Logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/metavia-announces-ai-driven-collaboration-with-syntekabio-to-explore-additional-indications-for-da-1241\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/metavia-announces-ai-driven-collaboration-with-syntekabio-to-explore-additional-indications-for-da-1241\\\/\",\"name\":\"MetaVia Announces AI-Driven Collaboration with Syntekabio to Explore Additional Indications for DA-1241 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/metavia-announces-ai-driven-collaboration-with-syntekabio-to-explore-additional-indications-for-da-1241\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/metavia-announces-ai-driven-collaboration-with-syntekabio-to-explore-additional-indications-for-da-1241\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2568660\\\/MetaVia_Logo.jpg\",\"datePublished\":\"2025-08-04T18:09:00+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/metavia-announces-ai-driven-collaboration-with-syntekabio-to-explore-additional-indications-for-da-1241\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/metavia-announces-ai-driven-collaboration-with-syntekabio-to-explore-additional-indications-for-da-1241\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/metavia-announces-ai-driven-collaboration-with-syntekabio-to-explore-additional-indications-for-da-1241\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2568660\\\/MetaVia_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2568660\\\/MetaVia_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/metavia-announces-ai-driven-collaboration-with-syntekabio-to-explore-additional-indications-for-da-1241\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MetaVia Announces AI-Driven Collaboration with Syntekabio to Explore Additional Indications for DA-1241\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"MetaVia Announces AI-Driven Collaboration with Syntekabio to Explore Additional Indications for DA-1241 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/metavia-announces-ai-driven-collaboration-with-syntekabio-to-explore-additional-indications-for-da-1241\/","og_locale":"en_US","og_type":"article","og_title":"MetaVia Announces AI-Driven Collaboration with Syntekabio to Explore Additional Indications for DA-1241 - Market Newsdesk","og_description":"PR Newswire Partnership Leverages Syntekabio’s DeepMatcher\u00ae Platform to Expand the Therapeutic Potential of MetaVia’s Oral GPR119 Agonist CAMBRIDGE, Mass. , Aug. 4, 2025 \/PRNewswire\/ — MetaVia Inc. (Nasdaq: MTVA),\u00a0a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced a research collaboration with Syntekabio, Inc., a leading artificial intelligence (AI)-driven drug discovery company, to identify additional disease targets and optimize the therapeutic profile of DA-1241, MetaVia’s novel oral G-Protein-Coupled Receptor 119 (GPR119) agonist. This collaboration follows positive results from MetaVia’s 16-week, 109-subject Phase 2a study of DA-1241, which demonstrated a favorable safety and tolerability profile alongside both hepatoprotective and glucose-regulating effects in presumed metabolic dysfunction-associated steatohepatitis (MASH) patients. “The strong safety and tolerability profile shown in our Phase 2a data … Continue reading \"MetaVia Announces AI-Driven Collaboration with Syntekabio to Explore Additional Indications for DA-1241\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/metavia-announces-ai-driven-collaboration-with-syntekabio-to-explore-additional-indications-for-da-1241\/","og_site_name":"Market Newsdesk","article_published_time":"2025-08-04T18:09:00+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/2568660\/MetaVia_Logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"8 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/metavia-announces-ai-driven-collaboration-with-syntekabio-to-explore-additional-indications-for-da-1241\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/metavia-announces-ai-driven-collaboration-with-syntekabio-to-explore-additional-indications-for-da-1241\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"MetaVia Announces AI-Driven Collaboration with Syntekabio to Explore Additional Indications for DA-1241","datePublished":"2025-08-04T18:09:00+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/metavia-announces-ai-driven-collaboration-with-syntekabio-to-explore-additional-indications-for-da-1241\/"},"wordCount":1524,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/metavia-announces-ai-driven-collaboration-with-syntekabio-to-explore-additional-indications-for-da-1241\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/2568660\/MetaVia_Logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/metavia-announces-ai-driven-collaboration-with-syntekabio-to-explore-additional-indications-for-da-1241\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/metavia-announces-ai-driven-collaboration-with-syntekabio-to-explore-additional-indications-for-da-1241\/","name":"MetaVia Announces AI-Driven Collaboration with Syntekabio to Explore Additional Indications for DA-1241 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/metavia-announces-ai-driven-collaboration-with-syntekabio-to-explore-additional-indications-for-da-1241\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/metavia-announces-ai-driven-collaboration-with-syntekabio-to-explore-additional-indications-for-da-1241\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/2568660\/MetaVia_Logo.jpg","datePublished":"2025-08-04T18:09:00+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/metavia-announces-ai-driven-collaboration-with-syntekabio-to-explore-additional-indications-for-da-1241\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/metavia-announces-ai-driven-collaboration-with-syntekabio-to-explore-additional-indications-for-da-1241\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/metavia-announces-ai-driven-collaboration-with-syntekabio-to-explore-additional-indications-for-da-1241\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/2568660\/MetaVia_Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/2568660\/MetaVia_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/metavia-announces-ai-driven-collaboration-with-syntekabio-to-explore-additional-indications-for-da-1241\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"MetaVia Announces AI-Driven Collaboration with Syntekabio to Explore Additional Indications for DA-1241"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/870182","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=870182"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/870182\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=870182"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=870182"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=870182"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}